Innovative drug to fight cancer

At Novartis Oncology, An employee has been discovering and developing innovative medicines to fight cancer. Now they are headquartered in Florham Park, New Jersey, they are passionate about providing various new solutions and practical solutions that change the way of life of patients with cancer.

More than 4,500 employees operating in more than 50 countries, Novartis Oncology has a range of truly global. they also have the advantage of exceptional employees who are talented and diverse globally, through shared goals and different perspectives, which is dedicated to improving and expanding the way of life for patients around the world.

They have a proven track record of providing new cancer treatments and better and continue to discover and develop new therapies that change lives better. This company was concentrating on the platform include discovery research efforts in the resistance signal transduction, cytotoxic agents, Antiangiogenesis, cell cyle / apoptosis, iron chelation, metastases and hormone therapy.

Visual expression to who we are and for who we become as an organization. We greatly appreciate and try to listen to open, open dialogue and open collaboration with public health and our employees. For more information, please visit: novartisoncology.com.

Research

Innovative drugs begins with research. Our research approach focused on the discovery of genetic studies in cell and rational drug design. Drug design involves the identification of tumor structure and developing drugs that would specifically target it. We have more than 120 collaborations with large biotech companies and more than 280 academic centers and has more than 150 clinical trials are underway.

For more information about the Novartis Institute for Biomedical Research (NIBR), please visit nibr.com.

After a promising drug has been identified, we work with leading researchers and patient volunteers in countries around the world to study the safety and efficacy of the agent. In cases where a drug under investigation shows efficacy in difficult access-to-treat population, we are considering to expand the development of these drugs through the Expanded Access Program (EAP) and regulatory mechanisms that are available. These programs allow patients access to experimental drugs between the time of filing and application for approval by health authorities. Novartis Oncology is one of the first companies to offer truly global Expanded Access Program.